Health Care Facilities

JOINT

JOINT released FY2026 Q1 earnings on May 7 After-Market (EST), actual revenue USD 14.82 M (forecast USD 14.5 M), actual EPS USD 0.0916 (forecast USD 0.03)

JOINT to Release FY2026 Q1 Earnings on May 7 After-Market EST, Forecast Revenue USD 14.5 M, EPS USD 0.03

JOINT released FY2025 Annual Earnings on March 13 After-Market EST, actual revenue USD 54.9 M (forecast USD 53.84 M), actual EPS USD 0.189 (forecast USD 0.135)

JOINT released FY2025 Q4 earnings on March 13 After-Market EST, actual revenue USD 15.17 M (forecast USD 14.12 M), actual EPS USD 0.067 (forecast USD 0.045)

JOINT to Release FY2025 Q4 Earnings on March 12 After-Market EST, Forecast Revenue USD 14.12 M, EPS USD 0.045

JOINT released FY2025 9 Months Earnings on November 6 After-Market EST, actual revenue USD 39.73 M, actual EPS USD 0.1145

JOINT released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 13.38 M (forecast USD 13.34 M), actual EPS USD 0.0557 (forecast USD -0.01)

JOINT to Release FY2025 Q3 Earnings on November 6 After-Market EST, Forecast Revenue USD 13.36 M, EPS USD -0.01

United Company Ranks 139th on Entrepreneur's Franchise 500 List

JOINT released FY2025 Q2 earnings on August 7 After-Market (EST), actual revenue USD 13.27 M (forecast USD 13.32 M), actual EPS USD 0.006 (forecast USD -0.0233)

JOINT released FY2025 Semi-Annual earnings on August 7 After-Market EST, actual revenue USD 26.35 M, actual EPS USD 0.0586

JOINT to Release FY2025 Q2 Earnings on August 7 After-Market EST, Forecast Revenue USD 13.32 M, EPS USD -0.0233

Joint Corp. Sells 31 Clinics and Secures Northwest Development Rights

The Joint Corp. launches mobile app

Joint Corp Sells Clinics and Secures Northwest Development Rights

JOINT Company Sells Clinics and Secures Development Rights

Joint Corp CFO Submits Beneficial Ownership Statement

JOINT Appoints Scott J. Bowman as CFO

Joint Corp Announces $5 Million Stock Repurchase Plan

JOINT released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 13.08 M (forecast USD 13.02 M), actual EPS USD 0.0637 (forecast USD 0.0025)

Agape ATP

Akanda

Co-Diagnostics

Netcapital

Tradr 2X Long QBTS Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Tradr 2X Long RGTI Daily ETF

PicoCELA

NewGenIvf

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

JYNT

INMB

Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)

businessinsider

Inmune Bio

iShares US Healthcare Providers

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

SPDR S&P Health

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VG Health

Proshares Ultra Nasdaq Biotech

Health Care Select Sector SPDR

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)

Earnings Watch

JOINT | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.82 M

Joint (JYNT) has signed an asset purchase agreement to sell 45 clinics in Southern California to Elite Chiro Group for approximately $2.3 million. This sale is part of its owned portfolio, and following this transaction, the number of corporate-managed locations will reduce to three out of about 960 total clinics. The company is also continuing its refranchising efforts for the remaining corporate-owned or managed clinics.

Fidelity

Joint Signs Deal to Sell 45 Clinics in California for $2.3 Million

The Joint Corp. to Report 2026 First Quarter Results on Thursday, May 7 and Host Conference Call and Webcast | JYNT Stock News

StockTitan

The Joint Corp. to Report 2026 First Quarter Results on Thursday, May 7 and Host Conference Call and Webcast | JYNT Stock News

CS精准医

516610

QC Kinetix has appointed Peter Holt, former CEO of The Joint Corp., as its new CEO to drive national growth. With over 40 years of experience in franchised organizations, Holt is expected to enhance QC Kinetix's infrastructure and support for clinic owners. His leadership is crucial as the company expands its network of clinics across the U.S. and adapts to the complexities of a larger healthcare organization. QC Kinetix, founded in 2017, is recognized as the largest regenerative medicine franchise in North America, focusing on non-surgical treatments for joint pain and musculoskeletal conditions.

MorningStar

Geratherm Medical AG

Dacheng CSI All Share Health Care Equipment and Services ETF

QC Kinetix Taps Former The Joint Corp. CEO Peter Holt to Lead Next Phase of National Growth

The Joint Corp. (NASDAQ: JYNT) has appointed Michelle Reap as the new Director of Franchise Development. With over 20 years of experience in the franchise industry, Reap will focus on strategic growth and connecting the brand with qualified partners for successful clinics. CEO Sanjiv Razdan emphasized her expertise in sustainable growth and aligning with The Joint's mission. The company operates over 950 clinics nationwide, providing accessible chiropractic care without insurance, and is recognized as a leader in the franchise sector.

The Joint Chiropractic® Names Michelle Reap as Director of Franchise Development | JYNT Stock News

JOINT(JYNT.US)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)

JOINT | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.82 M

Joint Signs Deal to Sell 45 Clinics in California for $2.3 Million

The Joint Corp. to Report 2026 First Quarter Results on Thursday, May 7 and Host Conference Call and Webcast | JYNT Stock News

QC Kinetix Taps Former The Joint Corp. CEO Peter Holt to Lead Next Phase of National Growth

The Joint Chiropractic® Names Michelle Reap as Director of Franchise Development | JYNT Stock News